. 2023 Feb 23;15(6):1277–1292. doi: 10.1016/j.jcmgh.2023.02.010

Table 1.

Clinical Trials With Antifibrotic Agents in Liver Fibrosis

Compound	Type	Phase	Trial number	Patients	Status	Treatment duration	Main result
Maraviroc	CCR-5 inhibitor	IV	NCT03129113	NAFLD and HIV	Completed	48 wk	No reduction of hepatic fat by MR-PDFF¹⁶⁵
Belapectin	Galectin 3 inhibitor	IIb	NCT02462967	NASH F4 cirrhosis with portal hypertension	Completed	52 wk	No reduction of HPVG, no histologic improvement¹⁶⁹
Simtuzumab (GS-6624)	Monoclonal antibody against LOXL2	IIb	NCT01672866	NASH F3/4 fibrosis	Completed	96 wk	No histologic improvement of hepatic collagen¹⁷⁰
Simtuzumab (GS-6624)	Monoclonal antibody against LOXL2	IIb	NCT01672879	NASH F4 cirrhosis	Completed	96 wk	No reduction of HPVG¹⁷⁰
Pirfenidone	Antifibrotic agent	II	NCT02161952.	Chronic hepatitis C	Completed	24 mo	Significant histologic improvement¹⁷¹
Pirfenidone	Antifibrotic agent	II	NCT04099407	Advanced fibrosis (mixed etiologies)	Completed	12 mo	Significant reduction of fibrosis by noninvasive measurement¹⁷²
BMS-986263	HSP47 siRNA	II	NCT03420768	Hepatitis C F3/4 fibrosis	Completed	12 wk	Association with histologic improvement¹⁷³
BMS-986263	HSP47 siRNA	II	NCT04267393	NASH compensated F4 cirrhosis	Recruiting
PLN-1474	Integrin αVβ1 inhibitor	I	not available	NASH F3/4 fibrosis	Recruiting

CCR-5, C-C chemokine receptor type 5; HPVG, hepatic venous pressure gradient; HSP47, Heat shock protein 47; LOXL2, Lysyl oxidase homolog 2; MR-PDFF, magnetic resonance proton density fat fraction; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.